Atopic Dermatitis Treated Safely with Dupilumab during Pregnancy: A Case Report and Review of the Literature
- PMID: 34177514
- PMCID: PMC8215998
- DOI: 10.1159/000515246
Atopic Dermatitis Treated Safely with Dupilumab during Pregnancy: A Case Report and Review of the Literature
Abstract
Dupilumab is currently the only biologic treatment approved for moderate-to-severe atopic dermatitis. Though limited, available clinical data describing dupilumab use in pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Systemic treatment in pregnant women with atopic dermatitis is currently restricted to corticosteroids, cyclosporine A, and azathioprine. Atopic dermatitis often has a deleterious course in pregnancy which can cause substantial distress and significantly impact on global health and quality of life. We report a case of severe atopic dermatitis treated safely with dupilumab during pregnancy with no adverse maternal or fetal outcomes observed. Our case highlights that dupilumab use in pregnancy has its place but should always be preceded by careful assessment of the risks and benefits. Clinicians are encouraged to enroll their patients in relevant pregnancy registry studies to monitor outcomes in women exposed to dupilumab during pregnancy and lactation.
Keywords: Atopic dermatitis; Dupilumab; Pregnancy.
Copyright © 2021 by S. Karger AG, Basel.
Conflict of interest statement
Dr Lobo has served as a sub-investigator for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Dermira, Eli Lilly, Galderma, Janssen, Leo Pharma, Mayne, Novartis, Pfizer, Sanofi, Sun Pharmaceuticals, and Union Chimique Belge. Dr Lee has served as a sub-investigator for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Dermira, Eli Lilly, Galderma, Janssen, Leo Pharma, Mayne, Novartis, Pfizer, Sanofi, Sun Pharmaceuticals, and Union Chimique Belge. Dr Spelman has served on advisory boards for AbbVie, Eli Lilly, Galderma, Janssen and Novartis; has served as an investigator for AbbVie, Amgen, Anacor, Ascend Biopharmaceuticals, Astellas, Australian Wool Innovation Limited, Blaze Bioscience, Boehringer Ingelheim, Bristol Myers Squibb, Botanix, Celgene, Dermira, Eli Lilly, Galderma, Genentech, GlaxoSmithKline, Janssen, Kythera, Leo Pharma, Mayne, Merck, Novartis, Pfizer, Phosphagenics, Regeneron, Sanofi, Sun Pharmaceuticals, Trius, and Union Chimique Belge; and has received sponsored travel from Abbott, Novartis, and Janssen.
Figures
Similar articles
-
Atopic Dermatitis with Multiple Comorbidities Treated with Dupilumab. A Case Report and Review of the Literature Regarding the Safety of Dupilumab.Life (Basel). 2022 Oct 21;12(10):1670. doi: 10.3390/life12101670. Life (Basel). 2022. PMID: 36295105 Free PMC article. Review.
-
The use of dupilumab in severe atopic dermatitis during pregnancy: a case report.Allergy Asthma Clin Immunol. 2022 Feb 3;18(1):9. doi: 10.1186/s13223-022-00650-w. Allergy Asthma Clin Immunol. 2022. PMID: 35115035 Free PMC article.
-
Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series.Clin Exp Dermatol. 2021 Aug;46(6):1089-1092. doi: 10.1111/ced.14725. Epub 2021 Jun 4. Clin Exp Dermatol. 2021. PMID: 33969522 Free PMC article.
-
Treatment of Severe Atopic Dermatitis with Dupilumab in Patients with Advanced Cancer.J Clin Med. 2023 Feb 2;12(3):1191. doi: 10.3390/jcm12031191. J Clin Med. 2023. PMID: 36769838 Free PMC article.
-
Dupilumab: A review of its use in the treatment of atopic dermatitis.J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1):S28-S36. doi: 10.1016/j.jaad.2017.12.022. J Am Acad Dermatol. 2018. PMID: 29471919 Review.
Cited by
-
Maternal, Fetal, and Labour Outcomes of Dupilumab Use for Atopic Dermatitis During Pregnancy: A Systematic Review.J Cutan Med Surg. 2025 Jan-Feb;29(1):51-55. doi: 10.1177/12034754241290806. Epub 2024 Oct 20. J Cutan Med Surg. 2025. PMID: 39428630 Free PMC article.
-
Big data- and machine learning-based analysis of a global pharmacovigilance database enables the discovery of sex-specific differences in the safety profile of dual IL4/IL13 blockade.Front Pharmacol. 2023 Oct 26;14:1271309. doi: 10.3389/fphar.2023.1271309. eCollection 2023. Front Pharmacol. 2023. PMID: 37954855 Free PMC article.
-
Atopic Dermatitis with Multiple Comorbidities Treated with Dupilumab. A Case Report and Review of the Literature Regarding the Safety of Dupilumab.Life (Basel). 2022 Oct 21;12(10):1670. doi: 10.3390/life12101670. Life (Basel). 2022. PMID: 36295105 Free PMC article. Review.
-
Dupilumab therapy in atopic dermatitis is safe during COVID-19 infection era: A systematic review and meta-analysis of 1611 patients.Dermatol Ther. 2022 Jun;35(6):e15476. doi: 10.1111/dth.15476. Epub 2022 Apr 7. Dermatol Ther. 2022. PMID: 35357060 Free PMC article.
-
Asthma in pregnancy.Allergy Asthma Proc. 2023 Jan 1;44(1):24-34. doi: 10.2500/aap.2023.44.220077. Allergy Asthma Proc. 2023. PMID: 36719688 Free PMC article. Review.
References
-
- Kage P, Simon JC, Treudler R. Atopic dermatitis and psychosocial comorbidities. J Dtsch Dermatol Ges. 2020 Feb;18((2)):93–102. - PubMed
-
- Treudler R. [Allergic diseases in pregnancy. Overview of diagnosis and therapy]. Hautarzt. 2010 Dec;61((12)):1027–33. - PubMed
-
- Treudler R, Zeynalova S, Riedel-Heller SG, Zuelke AE, Roehr S, Hinz A, et al. Depression, anxiety and quality of life in subjects with atopic eczema in a population-based cross-sectional study in Germany. J Eur Acad Dermatol Venereol. 2020 Apr;34((4)):810–6. - PubMed
-
- Vestergaard C, Wollenberg A, Barbarot S, Christen-Zaech S, Deleuran M, Spuls P, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 2019 Sep;33((9)):1644–59. - PubMed
-
- Australian Product Information. DupixentR (Dupilumab). 2020 Jun
Publication types
LinkOut - more resources
Full Text Sources